Published on
Apr 7, 2021
The European Commission Grants Marketing Authorization for New Subcutaneous Administration of TYSABRI® (natalizumab) to ...
TYSABRI is a well-established high-efficacy treatment that now provides two routes of administration enabling flexibility to meet patients' individual preferences and needs The subcutaneous option provides a shorter administration time and expands …
Distribution channels:
Media, Advertising & PR, Technology
...
